Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

Keyphrases

• Alzheimer's Disease Model 100%
• Amyloid beta 80%
• Amyloid Burden 100%
• Amyloid Deposition 20%
• Amyloid Plaques 20%
• Amyloid-β Peptide 100%
• Anti-amyloidogenic 20%
• Anti-inflammatory Cytokines 20%
• Astrocytic Activation 20%
• IgG2b 20%
• Immunological Approaches 20%
• Inflammatory Immune Response 20%
• Inflammatory Process 20%
• Mucosal Administration 40%
• Nasal Administration 100%
• Neuritic Dystrophy 20%
• Neuropathological Findings 20%
• PDAPP 20%
• Plaque Burden 20%
• Plasma Aβ42 20%
• Transgenic Lines 20%
• Tumor Growth Factor-β 20%
• Vascular Amyloid 100%

Neuroscience

• Amyloid Beta Protein 100%
• Amyloid Protein 100%
• Cancer Growth Factor 16%
• Immunoglobulin G1 16%
• Immunoglobulin G2b 16%
• Lymphatic Tissue 16%